The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development at Arcturus Therapeutics. Dr. Geller, known for his vast experience in pulmonology, has spent his career making a significant positive impact on children and adults with cystic fibrosis and chronic respiratory diseases. Joining the team at Arcturus uniquely positions Dr. Geller to accelerate the development of the next generation of mRNA medicines and have the potential to change the lives of patients suffering from diseases with significant unmet medical needs. In addition to guiding clinical project teams, Dr. Geller will provide strategic leadership within the Pulmonary and Rare Disease franchise ensuring the successful design and implementation of clinical development plans. The Chase Group was able to execute and complete this search in an expedited time frame given their depth of knowledge and network in the life science industry. TCG never loses sight of the profound impact their services have on the future success of an organization and looks forward to a continued partnership with Arcturus Therapeutics as they grow and unlock the potential of mRNA medicines. To learn more about collaborating with The Chase Group to build your executive team, please contact email@example.com.